Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2012

01-10-2012 | Case Report

A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge

Authors: Liesbeth Decoutere, Sabrina De Winter, Liesbeth Vander Weyden, Isabel Spriet, Maarten Schrooten, Jos Tournoy, Katleen Fagard

Published in: International Journal of Clinical Pharmacy | Issue 5/2012

Login to get access

Abstract

Case description A 85 year old woman with a history of severe depression treated with mirtazapine and venlafaxine was admitted to the hospital twice after progressive deterioration of her general condition evolving to unconsciousness. Clinicians diagnosed a metabolic encephalopathy caused by a urinary tract infection which was treated appropriately. Although mirtazapine was stopped during the first hospitalization, the patient’s general practitioner restarted mirtazapine four days before readmission. During rehospitalization, she developed extreme restlessness, hyperreflexia and an increased tone in the lower limbs. She was hypertensive and tachycardic. Excessive sweating, elevated creatine kinase levels and bilateral mydriasis were noticed. Urinary analysis showed positive levels of mirtazapine and venlafaxine and both drugs were withdrawn. Symptoms resolved within 48 h after discontinuation of her antidepressants. Conclusion To our knowledge, this is the first case of the serotonin syndrome confirmed by a positive challenge, de-challenge and re-challenge.
Literature
2.
go back to reference Dunkley EJ, Isbister GK. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(635):642. Dunkley EJ, Isbister GK. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(635):642.
3.
go back to reference Mason PJ, Morris VA, Balcezak TJ. Serotonin Syndrome: presentation of two cases and review of the literature. Medicine (Baltimore). 2000;79:201–9.CrossRef Mason PJ, Morris VA, Balcezak TJ. Serotonin Syndrome: presentation of two cases and review of the literature. Medicine (Baltimore). 2000;79:201–9.CrossRef
4.
go back to reference Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871–4.PubMed Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49:871–4.PubMed
5.
go back to reference Poeshla BD, Bartle P, Hansen KP. Serotonin syndrome associated with polypharmacy in the elderly. Gen Hosp Psychiatry. 2011;33(3):301.e9–11.CrossRef Poeshla BD, Bartle P, Hansen KP. Serotonin syndrome associated with polypharmacy in the elderly. Gen Hosp Psychiatry. 2011;33(3):301.e9–11.CrossRef
6.
go back to reference Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine. World J Biol Psychiatry. 2002;3:167. Letter.PubMedCrossRef Dimellis D. Serotonin syndrome produced by a combination of venlafaxine and mirtazapine. World J Biol Psychiatry. 2002;3:167. Letter.PubMedCrossRef
7.
go back to reference Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine and mirtazapine. Ann pharmacotherapy. 2004;38:411–3.CrossRef Houlihan DJ. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine and mirtazapine. Ann pharmacotherapy. 2004;38:411–3.CrossRef
8.
go back to reference Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotoninsyndrome: review. J Clin Psychopharmacol. 1997;17(3):208–21.PubMedCrossRef Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotoninsyndrome: review. J Clin Psychopharmacol. 1997;17(3):208–21.PubMedCrossRef
9.
10.
go back to reference Sato S, Yokota C, Toyoda K, Naganima M, Minematsu K. Hyperammonemic encephalopathy caused by urinary tract infection with urinary retention. Eur J Intern Med. 2008;19:e78–9.PubMedCrossRef Sato S, Yokota C, Toyoda K, Naganima M, Minematsu K. Hyperammonemic encephalopathy caused by urinary tract infection with urinary retention. Eur J Intern Med. 2008;19:e78–9.PubMedCrossRef
Metadata
Title
A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge
Authors
Liesbeth Decoutere
Sabrina De Winter
Liesbeth Vander Weyden
Isabel Spriet
Maarten Schrooten
Jos Tournoy
Katleen Fagard
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9666-7

Other articles of this Issue 5/2012

International Journal of Clinical Pharmacy 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.